We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





End-to-End Diagnostic Platform Could Be Game Changer for En-Masse, Rapid and Precise COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 27 Oct 2021

A new diagnostic platform could be a game-changing, end-to-end solution for en-masse, rapid and precise diagnosis of COVID-19 and other viruses at the point-of-care (POC). More...

Dotz Nano Ltd.’s (Kefar-Sava, Israel) Mega-Diagnostic Platform is an all-in-one solution that consists of proprietary DOTZ Test Kits, an integrated diagnostic system, and a results-management system. The Dotz Mega-Diagnostic Platform is based on RT-LAMP (Loop-Mediated Isothermal Amplification) technology with >95% true positive rate for viral loads of 1250 copies per mL; and 100% specificity.

Dotz’s platform provides an integrated and cost-efficient solution for SARS-CoV-2 testing that has the capacity to simultaneously test up to 96 samples per device in approximately 30 minutes. The test produces a visually-detectable change in the color of samples, ensuring a simple and rapid analysis procedure. The platform can use both saliva and nasopharyngeal samples for a more comfortable testing experience, particularly for children.

The Dotz Mega-Diagnostic Platform can be used in organizations or locations that are required to perform large numbers of tests in a short time, such as airports, universities, factories, workplaces, border crossings, and more. It requires minimal operator training, thereby significantly lowering overhead costs such as medical personnel and laboratory equipment. Dotz’s diagnostic solution has been granted CE Mark Authorization from the European Union, and it has also applied for Emergency Use Authorization from the FDA. Dotz will showcase its Mega-Diagnostic Platform for the first time at the MEDICA 2021 Trade Fair in Dusseldorf, Germany, November 15-18th.

“From the outbreak of the pandemic up to this point, en-masse and accurate detection of COVID-19 relied on complex and slow methods that must be performed in well-equipped laboratories by trained personnel,” said Gideon Shmuel, CEO of Dotz. “Our integrated, simple-to-use solution brings rapid and highly-accurate testing capabilities to the field, supporting a resumption of normal economic activity while keeping those transiting highly-trafficked public spaces healthy and safe.”

Related Links:
Dotz Nano Ltd. 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.